Targeting DNA With Fingers and TALENs.
Targeting DNA With Fingers and TALENs.
- Research Article
51
- 10.1038/mt.2010.57
- Jun 1, 2010
- Molecular Therapy
Gene Correction by Homologous Recombination With Zinc Finger Nucleases in Primary Cells From a Mouse Model of a Generic Recessive Genetic Disease
- Research Article
128
- 10.1074/jbc.r113.488247
- Feb 1, 2014
- Journal of Biological Chemistry
Human pluripotent stem cells (hPSCs) offer unprecedented opportunities to study cellular differentiation and model human diseases. The ability to precisely modify any genomic sequence holds the key to realizing the full potential of hPSCs. Thanks to the rapid development of novel genome editing technologies driven by the enormous interest in the hPSC field, genome editing in hPSCs has evolved from being a daunting task a few years ago to a routine procedure in most laboratories. Here, we provide an overview of the mainstream genome editing tools, including zinc finger nucleases, transcription activator-like effector nucleases, clustered regularly interspaced short palindromic repeat/CAS9 RNA-guided nucleases, and helper-dependent adenoviral vectors. We discuss the features and limitations of these technologies, as well as how these factors influence the utility of these tools in basic research and therapies.
- Research Article
147
- 10.1038/mt.2008.233
- Jan 1, 2009
- Molecular Therapy
Expanding or Restricting the Target Site Repertoire of Zinc-finger Nucleases: The Inter-domain Linker as a Major Determinant of Target Site Selectivity
- Research Article
75
- 10.1038/mt.2011.129
- Sep 1, 2011
- Molecular Therapy
Manipulating piggyBac Transposon Chromosomal Integration Site Selection in Human Cells
- Research Article
5
- 10.1038/mtna.2014.15
- May 1, 2014
- Molecular Therapy. Nucleic Acids
Although noncancerous immortalized cell lines have been developed by introducing genes into human and murine somatic cells, such cell lines have not been available in large domesticated animals like pigs. For immortalizing porcine cells, primary porcine fetal fibroblasts were isolated and cultured using the human telomerase reverse transcriptase (hTERT) gene. After selecting cells with neomycin for 2 weeks, outgrowing colonized cells were picked up and subcultured for expansion. Immortalized cells were cultured for more than 9 months without changing their doubling time (~24 hours) or their diameter (< 20 µm) while control cells became replicatively senescent during the same period. Even a single cell expanded to confluence in 100 mm dishes. Furthermore, to knockout the CMAH gene, designed plasmids encoding a transcription activator-like effector nuclease (TALENs) pairs were transfected into the immortalized cells. Each single colony was analyzed by the mutation-sensitive T7 endonuclease I assay, fluorescent PCR, and dideoxy sequencing to obtain three independent clonal populations of cells that contained biallelic modifications. One CMAH knockout clone was chosen and used for somatic cell nuclear transfer. Cloned embryos developed to the blastocyst stage. In conclusion, we demonstrated that immortalized porcine fibroblasts were successfully established using the human hTERT gene, and the TALENs enabled biallelic gene disruptions in these immortalized cells.
- Research Article
71
- 10.1038/mt.2012.284
- Jan 29, 2013
- Molecular Therapy
Generation of an HIV Resistant T-cell Line by Targeted “Stacking” of Restriction Factors
- Research Article
369
- 10.1038/mtna.2014.64
- Jan 1, 2014
- Molecular Therapy - Nucleic Acids
COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites.
- Research Article
214
- 10.1038/mt.2010.2
- Apr 1, 2010
- Molecular Therapy
A Transposon and Transposase System for Human Application
- Front Matter
17
- 10.1016/j.jhep.2023.01.017
- Jan 27, 2023
- Journal of Hepatology
Eliminating cccDNA to cure hepatitis B virus infection
- Research Article
84
- 10.1016/j.stem.2013.05.018
- Jun 1, 2013
- Cell Stem Cell
Therapeutic Translation of iPSCs for Treating Neurological Disease
- Research Article
71
- 10.1016/j.omtn.2017.02.007
- Feb 28, 2017
- Molecular Therapy - Nucleic Acids
CRISPR/Cas9-Mediated Genome Editing Corrects Dystrophin Mutation in Skeletal Muscle Stem Cells in a Mouse Model of Muscle Dystrophy.
- Research Article
12
- 10.1016/j.omtm.2020.10.017
- Oct 22, 2020
- Molecular Therapy - Methods & Clinical Development
Various mitochondrial diseases, including mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), are associated with heteroplasmic mutations in mitochondrial DNA (mtDNA). Herein, we refined a previously generated G13513A mtDNA-targeted platinum transcription activator-like effector nuclease (G13513A-mpTALEN) to more efficiently manipulate mtDNA heteroplasmy in MELAS-induced pluripotent stem cells (iPSCs). Introduction of a nonconventional TALE array at position 6 in the mpTALEN monomer, which recognizes the sequence around the m.13513G>A position, improved the mpTALEN effect on the heteroplasmic shift. Furthermore, the reduced expression of the new Lv-mpTALEN(PKLB)/R-mpTALEN(PKR6C) pair by modifying codons in their expression vectors could suppress the reduction in the mtDNA copy number, which contributed to the rapid recovery of mtDNA in mpTALEN-applied iPSCs during subsequent culturing. Moreover, MELAS-iPSCs with a high proportion of G13513A mutant mtDNA showed unusual properties of spontaneous, embryoid body-mediated differentiation in vitro, which was relieved by decreasing the heteroplasmy level with G13513A-mpTALEN. Additionally, drug-inducible, myogenic differentiation 1 (MYOD)-transfected MELAS-iPSCs (MyoD-iPSCs) efficiently differentiated into myosin heavy chain-positive myocytes, with or without mutant mtDNA. Hence, heteroplasmic MyoD-iPSCs controlled by fine-tuned mpTALENs may contribute to a detailed analysis of the relationship between mutation load and cellular phenotypes in disease modeling.
- Discussion
32
- 10.1038/mt.2010.92
- Jun 1, 2010
- Molecular Therapy
Gene Correction in Human Embryonic and Induced Pluripotent Stem Cells: Promises and Challenges Ahead
- Research Article
56
- 10.1038/mt.2013.143
- Sep 1, 2013
- Molecular Therapy
Targeted Gene Addition in Human Epithelial Stem Cells by Zinc-finger Nuclease-mediated Homologous Recombination
- Research Article
181
- 10.1016/j.stem.2019.04.001
- May 1, 2019
- Cell Stem Cell
Highly Efficient and Marker-free Genome Editing of Human Pluripotent Stem Cells by CRISPR-Cas9 RNP and AAV6 Donor-Mediated Homologous Recombination.
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.